Statement Of Cash Flows [Abstract]

Ascelia Pharma - Filing #678716

Concept 2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operations before changes in working capital
104 954 SEK
139 930 SEK
Increase (decrease) in working capital
21 838 SEK
14 667 SEK
Adjustments for decrease (increase) in trade and other receivables
1 620 SEK
1 362 SEK
Adjustments for increase (decrease) in other liabilities
11 033 SEK
5 456 SEK
Adjustments for decrease (increase) in other current assets
1 926 SEK
850,000 SEK
Cash flows from (used in) financing activities [abstract]
Payments for share issue costs
30,000 SEK
84,000 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.